Moderna, Inc. - MRNA STOCK NEWS

Flagship Pioneering has unveiled Abiologics, a company developing a new class of supranatural and programmable medicines called Synteins™. These are computationally-generated and synthesized with novel building blocks, aiming to overcome limitations of traditional biologics. The Abiologics platform uses generative AI and high-throughput chemical protein synthesis to create Synteins with extraordinary properties.

Flagship has initially committed $50 million to advance the platform and develop a pipeline of medicines, focusing on oncology and immunology. Synteins can be programmed to interact with virtually any therapeutic target while evading the body's natural defenses, offering advantages such as less frequent dosing, oral delivery, and access to previously unreachable parts of the body.

Moderna (NASDAQ:MRNA) announced it will report its second quarter 2024 financial results on Thursday, August 1, 2024, at 8:00 a.m. ET. The company will host a live conference call and webcast to discuss the results and provide a corporate update. The webcast will be accessible via the Investors section of Moderna's website and an archived version will be available approximately two hours after the event, remaining online for one year.

Moderna is a leader in mRNA medicine, known for developing one of the earliest and most effective COVID-19 vaccines. The company focuses on creating therapeutics and vaccines for various conditions, including infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. For more information, visit modernatx.com.

Flagship Pioneering, a bioplatform innovation company, announced it has raised $3.6 billion to foster the growth of 25 groundbreaking companies in human health, sustainability, and AI. This includes $2.6 billion into Fund VIII and $1 billion from sector-specific partnerships, bringing the total capital raised since 2021 to $6.4 billion. The company now operates with an aggregate capital pool of $10.9 billion and manages $14 billion in assets.

Flagship's recent partnerships include collaborations with Pfizer, Samsung, Thermo Fisher Scientific, and Novo Nordisk. These alliances are part of Flagship's Innovation Supply Chain Partnership (ISC) model, which maximizes innovation across various stages of product development.

The company has expanded globally, establishing hubs in London and Singapore to enhance its R&D collaborations and access international talent. Flagship has also bolstered its leadership team with several key hires and promotions to drive its growth and innovation strategy.

Flagship Pioneering, a bioplatform innovation company, has expanded its leadership team with new appointments and promotions. These changes accompany an expanded capital base of $3.6 billion for the development of 25 breakthrough platform companies in human health, sustainability, and AI.

Key promotions include Lovisa Afzelius to General Partner, Paul Biondi to General Partner, Dina Ciarimboli as General Counsel, Marcello Damiani as Senior Partner, Gary Pisano as Chief Strategist, and other critical roles filled by experienced professionals. These leaders bring significant expertise from major firms like Pfizer, Bristol-Myers Squibb, Moderna, and Harvard Business School.

Flagship aims to leverage these appointments to drive innovation, enhance strategic partnerships, and improve operational efficiency across its ecosystem of companies, furthering its mission to pioneer transformative technologies.

Moderna and Mitsubishi Tanabe Pharma have signed a joint agreement to co-promote Moderna’s mRNA respiratory vaccine portfolio in Japan, including the COVID-19 vaccine, Spikevax®. Moderna will manage manufacturing, sales, medical education, and distribution, while both companies will work together to maximize public health impact in Japan. The agreement spans from now until March 31, 2029, with undisclosed financial terms. The partnership aims to leverage Mitsubishi Tanabe Pharma's extensive experience in the Japanese market.

Moderna (NASDAQ:MRNA) announced a $176 million project award from BARDA’s Rapid Response Partnership Vehicle (RRPV) to accelerate mRNA-based pandemic influenza vaccine development. Funded by the U.S. Department of Health and Human Services (HHS), the project supports late-stage development for a pre-pandemic H5 influenza vaccine, addressing the highly infectious avian influenza virus. The agreement also includes options for future public health threat responses. Moderna’s CEO, Stéphane Bancel, highlighted the advantages of mRNA technology demonstrated during the COVID-19 pandemic. A Phase 1/2 study initiated in 2023 for the mRNA-1018 vaccine in adults will provide safety and immunogenicity data by 2024, informing Phase 3 plans.

Moderna has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on the marketing authorization for mRESVIA (mRNA-1345), their mRNA vaccine for respiratory syncytial virus (RSV). This vaccine is intended for adults aged 60 and older to protect against lower respiratory tract disease caused by RSV. The decision by the European Commission on the authorization of mRESVIA is pending.

RSV is a significant cause of lower respiratory infections and pneumonia, particularly affecting older adults. The CHMP's positive opinion is based on Phase 3 clinical trial data from the ConquerRSV study, which involved about 37,000 adults aged 60 and above in 22 countries. The trial showed a vaccine efficacy (VE) of 83.7% against RSV lower respiratory tract disease with a median follow-up of 3.7 months. With an 8.6-month follow-up, the vaccine showed sustained efficacy of 63.3%.

In May 2024, the U.S. FDA approved the vaccine under a breakthrough therapy designation. Moderna has also filed for marketing authorizations in various additional markets globally.

Moderna announced that its Phase 3 trial of mRNA-1283, a next-generation COVID-19 vaccine, met its primary efficacy endpoint.

The vaccine demonstrated non-inferior efficacy compared to Spikevax in participants aged 12 and older and higher efficacy in adults 18 and older.

The trial involved 11,400 individuals, half receiving 10 μg of mRNA-1283 and the other half 50 μg of Spikevax.

mRNA-1283 showed higher neutralizing antibody responses against Omicron BA.4/5 and ancestral SARS-CoV-2, especially in adults and those aged 65 and older.

Safety profiles were similar between mRNA-1283 and Spikevax, with common side effects being injection site pain, fatigue, headache, and myalgia.

Moderna plans to present the data at an upcoming conference and submit it for publication while engaging with regulators on the next steps.

Moderna announced positive results from its Phase 3 trial of the combination vaccine mRNA-1083 against influenza and COVID-19. The trial showed the vaccine elicited higher immune responses than licensed flu and COVID vaccines in adults 50 years and older. The study included approximately 8,000 participants split into two age cohorts: 50-64 and 65+. In both groups, mRNA-1083 significantly outperformed comparator vaccines for three influenza strains and the SARS-CoV-2 Omicron variant. The vaccine was found to be non-inferior in terms of safety and tolerability, with most adverse reactions being mild. Moderna plans to present these findings at a medical conference and seek regulatory approvals.